A Phase 2 interventional study of Cabozantinib and Placebo in Solid Tumors and Cancer, sponsored by Exelixis. Completed at 47 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-25.
Sponsored by Exelixis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
The goal of this clinical trial was to learn about the efficacy, safety, and tolerability of cabozantinib against a placebo in subjects with Metastatic Breast Cancer (MBC), Gastric and Gastroesophageal Junction Cancer (GEJ), Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Ovarian (primary peritoneal or fallopian tube carcinoma), Pancreatic Cancer, Castration-Resistant Prostate Cancer (CRPC), or Small cell Lung Cancer (SCLC) with advanced tumors.
The main questions this study aimed to answer were:
There were three stages to the Randomized Discontinuation Trial (RDT):
The Randomized Stage: Subjects who demonstrated stable disease (SD) at the end of 12 weeks of the Lead-in Stage were randomized to receive cabozantinib or placebo (a look-alike substance that contains no active drug) in a blinded manner.
After randomization, when a patient developed progressive disease (PD), study treatments were discontinued and the treatment blind was broken. If the subject was on a placebo, the subject was offered the opportunity to receive cabozantinib. If the subject was already on cabozantinib, the subject entered the Post-Treatment Period where they were followed until death.
The emerging data supported enrollment in an open-label, Non-Randomized Expansion cohort (NRE). These cohorts targeted patients with prostate and ovarian cancers. For the patients with prostate, they were assigned to either 100 mg, po QD or 39.4 mg, po QD.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 730 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or solid tumor of the nine types listed below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open Label, cabozantinib, 100 mg, po QD for 12 weeks.
Drug: Cabozantinib
Blinded, cabozantinib, 100 mg, po QD until disease progression.
Drug: Cabozantinib
Blinded, placebo, 100 mg, po QD until disease progression.
Drug: Placebo
Open Label, cabozantinib, for subjects that were on placebo during the randomized stage, 100 mg, po QD until disease progression or unacceptable toxicity.
Drug: Cabozantinib
Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.
Drug: Cabozantinib
Open Label, cabozantinib, 39.4, po QD until disease progression or unacceptable toxicity.
Drug: Cabozantinib
Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.
Drug: Cabozantinib
Also known as: XL184
Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only
Objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.0 per investigator The analysis of ORR in the RDT Cohorts were defined as the proportion of subjects with a best overall response of confirmed complete response (CR) or partial response (PR) per mRECIST 1.0 during the 12-week Lead-In Stage. In the NRE Ovarian Cohort, mRECIST 1.1 was used. ORR for the NRE CRPC Cohorts was not a primary objective and is therefore not captured in the table below.
Time frame: From initial dose through final study visit up to 44 months
Bone Scan Response (BSR) - NRE, CRPC
The reduction of bone scan lesion area (BSLA) by \> 30% was used as the quantitative measure of BSR. BSR was a primary outcome measure for only the NRE CRPC Cohorts.
Time frame: From initial dose through final study visit up to 15 months
Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only
Progression Free Survival during the Randomized Stage (Randomized Population)
Time frame: From initial dose through final study visit up to 44 months
Duration of Objective Response (OR) - Responders From Lead-in Stage
Duration of objective response was defined as the time from the tumor assessment that first documented PR or CR that was subsequently confirmed at least 28 days later until the date of documented progression. There were either few or no responders in the Gastric/GEJ, SCLC, and pancreatic cohorts so these cohorts are excluded.
Time frame: From initial dose through final study visit up to 44 months
Progression Free Survival (PFS) - Throughout the Study
Progression-free survival (PFS) from first dose throughout the study was estimated for all subjects (safety population) using a piecewise method.
Time frame: From initial dose through final study visit up to 44 months
Duration of Bone Scan Response - NRE Cohorts, CRPC Only
The duration of BSR per IRF was calculated for CRPC subjects with an objective response (CR or PR) during the study.
Time frame: From initial dose through final study visit up to 15 months
Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only
Time frame: From initial dose through final study visit up to 15 months
| Milestone | RDT Cohort - Castration-Resistant Prostate Cancer (CRPC) | RDT Cohort - Melanoma | RDT Cohort - Non-Small Cell Lung Cancer (NSCLC) | RDT Cohort - Pancreatic Cancer | RDT Cohort - Gastric/Gastroesophageal Junction Cancer (GEJ) | RDT Cohort - Hepatocellular Carcinoma (HCC) | RDT Cohort - Small Cell Lung Cancer (SCLC) | RDT Cohort - Ovarian Cancer | RDT Cohort - Metastatic Breast Cancer (MBC) | NRE Cohort - CRPC 100 mg | NRE Cohort - CRPC 39.4 mg | NRE Cohort - Ovarian Cancer 100mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 171 | 77 | 60 | 20 | 21 | 41 | 21 | 70 | 45 | 93 | 51 | 60 |
| Completed | 156 | 66 | 47 | 16 | 19 | 36 | 20 | 60 | 41 | 87 | 48 | 54 |
| Not completed | 15 | 11 | 13 | 4 | 2 | 5 | 1 | 10 | 4 | 6 | 3 | 6 |
Objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.0 per investigator The analysis of ORR in the RDT Cohorts were defined as the proportion of subjects with a best overall response of confirmed complete response (CR) or partial response (PR) per mRECIST 1.0 during the 12-week Lead-In Stage. In the NRE Ovarian Cohort, mRECIST 1.1 was used. ORR for the NRE CRPC Cohorts was not a primary objective and is therefore not captured in the table below.
| percentage of participants | Lead-in Stage - CRPC | Lead-in Stage - Melanoma | Lead-in Stage - NSCLC | Lead-in Stage - Pancreatic Cancer | Lead-in Stage - Gastric/GEJ | Lead-in Stage - Hepatocellular Carcinoma | Lead-in Stage - SCLC | Lead-in Stage - Ovarian Cancer | Lead-in Stage - Metastatic Breast Cancer | Lead-in Stage - NRE Ovarian Cancer |
|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only | 4.7 (2.0 to 8.7) | 5.2 (1.8 to 12.4) | 10 (4.4 to 20.3) | 0 (0 to 15.4) | 4.8 (0.2 to 21.8) | 4.9 (0.9 to 16.1) | 4.8 (0.2 to 21.8) | 21.7 (13.1 to 32.4) | 13.6 (6.0 to 25.7) | 10.0 (3.3 to 21.8) |
The reduction of bone scan lesion area (BSLA) by \> 30% was used as the quantitative measure of BSR. BSR was a primary outcome measure for only the NRE CRPC Cohorts.
| percentage of participants | NRE Cohort - CRPC 100 mg | NRE Cohort - CRPC 39.4 mg |
|---|---|---|
| Bone Scan Response (BSR) - NRE, CRPC | 74.2 (64.1 to 82.7) | 47.1 (32.9 to 61.5) |
Progression Free Survival during the Randomized Stage (Randomized Population)
| months | Randomized Phase - CRPC, Cabozantinib Arm | Randomized Phase - CRPC, Placebo Arm | Randomized Phase - Melanoma, Cabozantinib Arm | Randomized Phase - Melanoma, Placebo Arm | Randomized Phase - NSCLC, Cabozantinib Arm | Randomized Phase - NSCLC, Placebo Arm | Randomized Phase - Pancreatic Cancer, Cabozantinib Arm | Randomized Phase - Pancreatic Cancer, Placebo Arm | Randomized Phase - Gastric/GEJ, Cabozantinib Arm | Randomized Phase - Gastric/GEJ , Placebo Arm | Randomized Phase - HCC, Cabozantinib Arm | Randomized Phase - HCC, Placebo Arm | Randomized Phase - SCLC, Cabozantinib Arm | Randomized Phase - SCLC, Placebo Arm | Randomized Phase - Ovarian Cancer, Cabozantinib Arm | Randomized Phase - Ovarian Cancer, Placebo Arm | Randomized Phase - MBC, Cabozantinib Arm | Randomized Phase - MBC, Placebo Arm |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only | 5.5 (4.0 to 8.5) | 1.4 (1.25 to 2.73) | 4.5 (1.8 to 15.4) | 2.8 (1.45 to 5.45) | 2.4 (1.3 to 2.9) | 2.4 (1.4 to 2.7) | 2.8 (1.5 to 2.8) | .07 (.07 to .07) | NA (2.3 to NA) | 1.0 (.72 to 1.38) | 2.5 (1.3 to 6.8) | 1.4 (1.3 to 4.2) | 5.5 (1.9 to 6.9) | 1.5 (.85 to 2.23) | 4.9 (3.9 to 13.6) | 1.4 (1.3 to 1.6) | 6.9 (5.1 to 13.5) | 1.1 (.7 to 1.3) |
Duration of objective response was defined as the time from the tumor assessment that first documented PR or CR that was subsequently confirmed at least 28 days later until the date of documented progression. There were either few or no responders in the Gastric/GEJ, SCLC, and pancreatic cohorts so these cohorts are excluded.
| Months | CRPC | Melanoma | NSCLC | Hepatocellular Carcinoma | Ovarian Cancer | Metastatic Breast Cancer |
|---|---|---|---|---|---|---|
| Duration of Objective Response (OR) - Responders From Lead-in Stage | 5.59 (4.27 to 8.34) | 5.55 (2.99 to 13.86) | 6.90 (5.29 to 10.74) | 4.21 (2.99 to NA) | 11.24 (7.20 to NA) | 3.29 (2.79 to 4.21) |
Progression-free survival (PFS) from first dose throughout the study was estimated for all subjects (safety population) using a piecewise method.
| months | CRPC | Melanoma | NSCL | Pancreatic Cancer | Gastric/GEJ | Hepatocellular Carcinoma | SCLC | Ovarian Cancer | Metastatic Breast Cancer |
|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) - Throughout the Study | 6.8 (3.9 to 9.7) | 2.8 (1.4 to 6.9) | 4.0 (1.4 to 5.7) | 2.7 (1.3 to 5.5) | 1.4 (1.3 to NA) | 5.2 (3.6 to 9.3) | 3.4 (1.4 to 8.2) | 5.5 (2.7 to 11.0) | 4.3 (1.4 to 8.1) |
The duration of BSR per IRF was calculated for CRPC subjects with an objective response (CR or PR) during the study.
| months | NRE Cohort - CRPC 100 mg | NRE Cohort - CRPC 39.4 mg |
|---|---|---|
| Duration of Bone Scan Response - NRE Cohorts, CRPC Only | 5.2 (4.07 to 6.67) | NA (NA to NA) |
| months | NRE Cohort - CRPC 100 mg | NRE Cohort - CRPC 39.4 mg | NRE Cohort - Ovarian 100 mg |
|---|---|---|---|
| Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only | 11.1 (9.17 to 13.34) | 8.0 (7.92 to NA) | 8.5 (5.88 to 11.73) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RDT All Cohorts | 54/526 (10.3%) | 223/526 (42.4%) | 524/526 (99.6%) |
| NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | 53/93 (57%) | 53/93 (57%) | 93/93 (100%) |
| NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | 13/51 (25.5%) | 30/51 (58.8%) | 50/51 (98%) |
| NRE Cohort - Ovarian 100mg | 33/60 (55%) | 34/60 (56.7%) | 59/60 (98.3%) |
| Event | RDT All Cohorts | NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | NRE Cohort - Ovarian 100mg |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 15/526 | 7/93 | 0/51 | 11/60 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 23/526 | 7/93 | 8/51 | 1/60 |
| NauseaGastrointestinal disorders | 12/526 | 9/93 | 0/51 | 8/60 |
| Abdominal PainGastrointestinal disorders | 9/526 | 2/93 | 2/51 | 7/60 |
| Small Intestinal ObstructionGastrointestinal disorders | 5/526 | 0/93 | 0/51 | 5/60 |
| Back PainMusculoskeletal and connective tissue disorders | 5/526 | 5/93 | 4/51 | 0/60 |
| Intestinal ObstructionGastrointestinal disorders | 3/526 | 0/93 | 0/51 | 4/60 |
| PyrexiaGeneral disorders | 5/526 | 2/93 | 0/51 | 4/60 |
| DehydrationMetabolism and nutrition disorders | 17/526 | 6/93 | 2/51 | 0/60 |
| Bone PainMusculoskeletal and connective tissue disorders | 0/526 | 6/93 | 1/51 | 0/60 |
| Event | RDT All Cohorts | NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | NRE Cohort - Ovarian 100mg |
|---|---|---|---|---|
| FatigueGeneral disorders | 345/526 | 76/93 | 32/51 | 47/60 |
| DiarrhoeaGastrointestinal disorders | 314/526 | 66/93 | 23/51 | 46/60 |
| Decreased AppetiteMetabolism and nutrition disorders | 270/526 | 70/93 | 22/51 | 31/60 |
| NauseaGastrointestinal disorders | 269/526 | 64/93 | 30/51 | 36/60 |
| Weight DecreasedInvestigations | 165/526 | 42/93 | 19/51 | 18/60 |
| VomitingGastrointestinal disorders | 188/526 | 38/93 | 19/51 | 25/60 |
| Abdominal PainGastrointestinal disorders | 120/526 | 17/93 | 8/51 | 23/60 |
| DysgeusiaNervous system disorders | 156/526 | 35/93 | 14/51 | 21/60 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 142/526 | 34/93 | 9/51 | 16/60 |
| ConstipationGastrointestinal disorders | 168/526 | 32/93 | 16/51 | 21/60 |
| Age, Customized(Participants) | RDT Cohort - CRPC | RDT Cohort - Melanoma | RDT Cohort - NSCLC | RDT Cohort - Pancreatic Cancer | RDT Cohort - GEJ | RDT Cohort - HCC | RDT Cohort - SCLC | RDT Cohort - Ovarian Cancer | RDT Cohort - MBC | NRE Cohort - CRPC 100 mg | NRE Cohort - CRPC 39.4 mg | NRE Cohort - Ovarian Cancer 100mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <= 40 years | 0 | 5 | 1 | 1 | 1 | 4 | 0 | 4 | 6 | 0 | 0 | 1 | 23 |
| > 40 - <= 50 years | 4 | 6 | 3 | 1 | 3 | 3 | 2 | 12 | 7 | 3 | 5 | 10 | 59 |
| > 50 - <= 65 years | 60 | 28 | 23 | 11 | 9 | 22 | 12 | 32 | 26 | 41 | 24 | 33 | 321 |
| > 65 years | 107 | 38 | 33 | 7 | 8 | 12 | 7 | 22 | 6 | 49 | 22 | 16 | 327 |
| Sex: Female, Male(Participants) | RDT Cohort - CRPC | RDT Cohort - Melanoma | RDT Cohort - NSCLC | RDT Cohort - Pancreatic Cancer | RDT Cohort - GEJ | RDT Cohort - HCC | RDT Cohort - SCLC | RDT Cohort - Ovarian Cancer | RDT Cohort - MBC | NRE Cohort - CRPC 100 mg | NRE Cohort - CRPC 39.4 mg | NRE Cohort - Ovarian Cancer 100mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 35 | 27 | 7 | 5 | 10 | 12 | 70 | 44 | 0 | 0 | 60 | 270 |
| Male | 171 | 42 | 33 | 13 | 16 | 31 | 9 | 0 | 1 | 93 | 51 | 0 | 460 |
| Race (NIH/OMB)(Participants) | RDT Cohort - CRPC | RDT Cohort - Melanoma | RDT Cohort - NSCLC | RDT Cohort - Pancreatic Cancer | RDT Cohort - GEJ | RDT Cohort - HCC | RDT Cohort - SCLC | RDT Cohort - Ovarian Cancer | RDT Cohort - MBC | NRE Cohort - CRPC 100 mg | NRE Cohort - CRPC 39.4 mg | NRE Cohort - Ovarian Cancer 100mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 12 | 2 | 2 | 0 | 1 | 15 | 1 | 0 | 1 | 1 | 1 | 4 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 11 | 2 | 6 | 2 | 1 | 3 | 1 | 0 | 1 | 4 | 2 | 2 | 35 |
| White | 145 | 72 | 51 | 18 | 19 | 22 | 18 | 66 | 41 | 85 | 45 | 51 | 633 |
| More than one race | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 0 | 1 | 9 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 12 |
Ran from Sep 2009 to primary completion in May 2013, 44 months.
Results were first posted in Apr 2024, 10 years 11 months after primary completion.
Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 44 months is close to that.
Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib